Axsome Therapeutics (AXSM) Misses Q2 EPS by 14c

Axsome Therapeutics (NASDAQ: AXSM) reported Q2 EPS of ($0.99), $0.14 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $218.37 million versus the consensus estimate of $221.92 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• Methode Electronics (MEI) Tops Q1 EPS by 2c; offers guidance
• PVH Corp. (PVH) Tops Q2 EPS by 62c, Beats on Revenue; Offers FY27 EPS Guidance
• After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE